HEMODYNAMIC DISORDERS, THROMBOEMBOLISM, AND SHOCK 2





 Normal hemostasis comprises a series of regulated processes that culminate in the formation of a <u>blood clot</u> that limits bleeding from an <u>injured vessel</u>.

• The pathologic counterpart of hemostasis is thrombosis, the formation of blood clot (thrombus) within non-traumatized, intact vessels.




NORMAL HEMOSTASIS

1+2 +3 Cp paremeters

or 195 miles

- Hemostasis is process involving platelets, clotting factors, and
- endothelium that occurs at the site of vascular injury and culminates in the formation of a blood clot, which serves to prevent or limit the extent of bleeding.



MAJOR COMPONENT OF HEMOSTASIS

1.platelates


2.Clotting factors


3.Endothelium

THE GENERAL SEQUENCE OF EVENTS LEADING TO HEMOSTASIS AT A SITE OF VASCULAR INJURY INCLUDE: I. PRIMARY HEMOSTASIS


- 1. ARTERIOLAR VASOCONSTRICTION:
- occurs immediately and markedly reduces blood flow to the injured area.
- it is mediated by reflex neurogenic mechanisms.
- it is augmented by endothelin, a potent endothelium-derived vasoconstrictor.
- this effect is transient, however, bleeding would resume if not followed by

activation of platelets and coagulation factors.





- 2. PLATELET ACTIVATION
- THE FORMATION OF THE PLATELET PLUG.





PLATELETS

بدعله/ تغلق

• platelets play a critical role in hemostasis by forming the primary plug that initially seals vascular defects and by providing a surface that binds and concentrates activated coagulation factors.

• platelets are disc-shaped anucleate cell fragments that are shed from megakaryocytes in

the bone marrow into the bloodstream.

WWF Do von Willebrand factor.


(4) = 195 ml = 181 & platelet 11 7/71 l





• 1. PLATELET ADHESION:

• is mediated via interactions with vwf, which acts as a bridge between the platelet surface receptor glycoprotein ib (gpib) and exposed collagen.





- <u>A. CHANGES IN SHAPE</u> from smooth discs to "spiky "with greatly increased surface area.
- alterations in glycoprotein iib/iiia that increase its affinity for fibrinogen
- (3) the translocation of negatively charged phospholipids to the platelet surface

- B. SECRETION OF GRANULE CONTENTS, e.g.
- ADP: create an additional rounds of platelet activation.
- (3√ THROMBOXANE A2 (TXA2): a potent inducer of platelet aggregation.


3. PLATELET AGGREGATION FOLLOWS THEIR ACTIVATION.

• The conformational change in glycoprotein iib/iiia allows binding of fibrinogen that forms bridges between adjacent platelets, leading to their aggregation.

√ fibrinogén cause reversible aggregation

✓ thrombin cause irreversible aggregation (converts fibrinogen into insoluble fibrin).

✓ cytoskeleton cause contraction of the plug.



need thrombin


RY HEMOSTASIS:

Librinogen is soit

DEPOSITION OF FIBRIN.

(w. 2) of secondary hernostasis VASCULAR INJURY EXPOSES TISSUE FACTOR AT THE SITE OF INJURY.

• TISSUE FACTOR BINDS AND ACTIVATES FACTOR $\boxed{1}$, SETTING IN MOTION A CASCADE OF REACTIONS THAT CULIMINATES IN THROMBIN GENERATION.




M. CLOT STABILIZATION AND RESORPTION:

• polymerized fibrin and platelet aggregates undergo contraction to form a solid, permanent plug that prevents further hemorrhage.

• entrapped red cells and leukocytes are also found in hemostatic plugs, in part due to adherence of leukocytes to p-selectin expressed on activated platelet

• at this stage, counterregulatory mechanisms (e.g., tissue plasminogen activator, t-pa made by endothelial cells) are set into motion that limit clotting to the site of injury, and eventually lead to clot resorption and tissue repair.






COAGULATION CASCADE

• the coagulation cascade is a series of amplifying enzymatic reactions that lead to the deposition of an insoluble fibrin clot.

each reaction step involves an enzyme (an activated coagulation factor), a substrate (an inactive proenzyme form of a coagulation factor), and a cofactor (a reaction accelerator).


• these components are assembled on a negatively charged phospholipid surface, which is provided by activated platelets. assembly of reaction complexes also depends on calcium







Coagulation cascade has traditionally been divided into the extrinsic and intrinsic pathways



- 1.THE PROTHROMBIN TIME (PT)
- ASSAY ASSESSES THE FUNCTION OF THE PROTEINS IN THE EXTRINSIC PATHWAY (FACTORS VII, IV) X, V, II (PROTHROMBIN), AND FIBRINGEN).
 - THE PARTIAL THROMBOPLASTIN TIME (PTT)
- ASSAY SCREENS THE FUNCTION OF THE PROTEINS IN THE INTRINSIC PATHWAY (FACTORS XII,
- XI, IX, VIII, X, V, II, AND FIBRINGEN.





MONG PHROMBIN'S MOST IMPORTANT ACTIVITIES ARE THE JI Changin **FOLLOWING:**

CONVERSION OF FIBRINOGEN INTO CROSSLINKED FIBRIN.

How?

- THROMBIN DIRECTLY CONVERTS SOLUBLE FIBRINOGEN INTO FIBRIN MONOMERS THAT POLYMERIZE INTO AN INSOLUBLE FIBRIL.
- 2.PLATELET ACTIVATION.
- 4. ANTI-COAGULANT EFFECTS.
- ENCOUNTERING NORMAL ENDOTHELIUM, THROMBIN CHANGES FROM A PROCOAGULANT TO

AN ANTICOAGULANT.

Anticagulant کی یت فقر ویترکول کا Hrombin کا نوخ ا

مین نامی الد Coagulant J راندیا



FACTORS THAT LIMIT COAGULATION.

- coagulation must be restricted to the site of vascular injury to prevent dangerous consequences through:
- 1.simple dilution:
- blood flowing at the site of injury washes out activated coagulation factors, which are rapidly removed by the liver.
- 2.requirement for negatively charged phospholipids if placelet عبنا not activated algorithm of fibrir (ve والمناف المناف ا
- through the enzymatic activity of plasmin, which breaks down fibrin and interferes with its polymerization.

fibrinolytic cascade plasmingen, log = Plasminogen activators Tissue plasminogen activator (tPA), fibrin المربقين عده injury مربقين عده المربية أنه المربية الم urokinase, streptokinase staphylokinase, vampire bat PA PAI-1 Cleave (inhibits tPA, plasminogen into present in blood active plasmin in small concentration) Plasmin Jz Pins **Plasmin** Plasminogen α₂-antiplasmin Pibrin بکسر اد Degrades (physiological inhibitor of fibrin clot, plasmin present in blood in concentration وسيكل الحروة جوا الأوبي core of 6-8X exceeding therapeutic dose of plasmin) thrombus Fibrin degradation **Fibrin** products



 AN ELEVATED LEVEL OF BREAKDOWN PRODUCTS OF FIBRINOGEN (D-DIMERS) ARE A USEFUL CLINICAL MARKERS OF SEVERAL THROMBOTIC STATES

D-Dimer





ENDOTHELIUM

• The balance between the anticoagulant and procoagulant activities of endothelium often determines whether clot formation, propagation, or dissolution occurs.

pro intact
antico

+ Mechanisims help endothelium to act as anticoagulant:

1.PLATELET INHIBITORY EFFECTS:

- serve as a barrier that shields platelets from subendothelial vwf and collagen.
- ✓ releases a number of factors that inhibit platelet activation and aggregation. among the most important are prostacyclin (pgi2), nitric oxide (no).
 - endothelial cells bind and alter the activity of thrombin, which is one of the most potent activators of platelets.

2. ANTICOAGULANT EFFECTS.

 normal endothelium shields coagulation factors from tissue factor in vessel walls and expresses multiple factors that actively oppose coagulation:

MOST NOTABLY thrombomodulin, endothelial protein c receptor, heparin-like molecules, and tissue factor pathway inhibitor.



